- Cytosorbents
-
Cytosorbents 
Type Public Industry Biomedicine Headquarters Monmouth Junction, New Jersey, USA Key people Phillip P. Chan, MD, PhD (President and CEO) Products CytoSorb™ Services Anti-inflammatory agents Website http://www.cytosorbents.com Cytosorbents Inc (OTCBB: CTSO), formerly MedaSorb Technologies, Inc is a Monmouth Junction based biotechnology company whose most advanced product candidate is Cytosorb for sepsis. In March 2011, Cytosorb™ obtained CE Mark approval in Europe as cytokine filter used to reduce the cytokine storm found in sepsis patients. CytoSorb™ plus SOC lowered IL-6 levels by an average of 49.1% (p = 0.01) during the CytoSorb™ treatment period vs standard of care alone.[1] The company plans to first commercialize the product in Europe.[2]
Cytosorb™
Comparison of similar products
The 28-day mortality rate of Cytosorb-treated patients has not yet been released (as of July 24, 2011), yet the device was still able to achieve the CE mark. Enrollment in the 100 patient trial[3] has already been completed.[2]
Xigris, by Eli Lilly and Company, had a 6.1% reduction of 28-day mortality of all patients (vs standard of care), and 13.0% in patients with APACHE II score > 24.[4]
Toraymyxin, (Polymyxin B fiber column), by Toray had 28 day mortality reduced by 21% compared to the conventional therapy group.[5] Toraymyxin is not available in the US. It should be noted that Toraymyxin treats endotoxemia, which involves endotoxins, whereas Cytosorb treats the cytokine storm. Endotoxins can lead to a cytokine storm,[6] so by the time the patient reaches the hospital, the cytokine storm may be well underway.
Notes
- ^ "Cytosorb Primary Endpoint Data". http://www.cytosorbents.com/news41.htm.
- ^ a b "10-Q May 2011". http://www.sec.gov/Archives/edgar/data/1175151/000114420411030089/v222408_10q.htm.
- ^ "Cytosorb trial site". http://clinicaltrials.gov/ct2/show/NCT00559130?term=medasorb&rank=1.
- ^ Warren HS, Suffredini AF, Eichacker PQ, Munford RS (September 2002). "Risks and benefits of activated protein C treatment for severe sepsis". N. Engl. J. Med. 347 (13): 1027–30. doi:10.1056/NEJMsb020574. PMID 12324562.
- ^ EUPHAS trial. PMID 19531784.
- ^ "Toraymyxin". http://www.toray.com/news/medical/nr070629.html.
Categories:- Companies listed on the OTC Bulletin Board
- Biotechnology companies
- Companies based in New Jersey
- Pharmaceutical companies of the United States
Wikimedia Foundation. 2010.
